Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Haleon PLC ( (GB:HLN) ) is now available.
Haleon has repurchased 7,833,121 ordinary shares for cancellation under its share buyback programme, with purchases executed between 16 and 20 March 2026 across venues including the London Stock Exchange and Cboe UK. Following these transactions, Haleon’s share capital stands at 8,941,771,041 ordinary shares, of which 12,591,821 are held in treasury, leaving 8,929,179,220 shares with voting rights, a figure relevant for investors monitoring disclosure thresholds under UK transparency rules.
The reduction in Haleon’s free-float through buybacks and the increase in treasury holdings may enhance earnings per share and signal confidence in the company’s valuation, while also slightly concentrating ownership among remaining shareholders. The updated share count and voting rights position are important for institutional investors and other stakeholders tracking their holdings against regulatory reporting requirements and potential future corporate actions.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £512.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global consumer health company focused on improving everyday health through over-the-counter products across six categories, including oral health, vitamins, minerals and supplements, pain relief, respiratory, digestive and therapeutic skin health. Its portfolio features well-known brands such as Sensodyne, Panadol, Voltaren, Advil and Centrum, which are trusted by over one billion consumers and recommended by health professionals worldwide.
Average Trading Volume: 18,633,563
Technical Sentiment Signal: Strong Buy
Current Market Cap: £33.46B
See more data about HLN stock on TipRanks’ Stock Analysis page.